CTLA4 and neoplasm: For example, immune checkpoint inhibitors have revolutionized modern cancer treatment by targeting inhibitory receptors (e.g., PD-1, CTLA-4, LAG-3), ligands (e.g., PD-L1) expressed on T cells, antigen-presenting cells, and tumor cells, which result in an anti-tumor response by stimulating the host immune system.